<DOC>
	<DOCNO>NCT01737684</DOCNO>
	<brief_summary>This study investigate pharmacokinetics single oral dose vibegron ( MK-4618 ) administer participant moderate hepatic insufficiency healthy participant match age , gender , body mass index ( BMI ) . Participants may enrol mild hepatic insufficiency .</brief_summary>
	<brief_title>A Single-Dose Study Pharmacokinetics Vibegron ( MK-4618 ) Adults With Hepatic Insufficiency ( MK-4618-013 )</brief_title>
	<detailed_description>This study plan conduct two part . Part 1 study include participant moderate hepatic insufficiency healthy participant . If Part 2 conduct , Part 2 study include participant mild hepatic insufficiency .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Inclusion Criteria For healthy participant participant hepatic insufficiency : Continuous nonsmoker n't use nicotinecontaining product least 3 month prior study drug administration Body mass index ( BMI ) â‰¤39 kg/m^2 Good health base medical history , physical examination , vital sign , laboratory safety test , electrocardiogram ( ECG ) Females childbearing potential must sexually inactive 14 day prior study drug administration throughout study use acceptable birth control method Females nonchildbearing potential must undergo acceptable sterilization procedure least 6 month prior Day 1 study postmenopausal amenorrhea least 1 year prior Day 1 Nonvasectomized male must agree use condom spermicide abstain sexual intercourse trial 3 month study drug administration For participant hepatic insufficiency : Diagnosis chronic , stable , hepatic insufficiency For Part 1 Participants : ChildPugh scale range 7 9 For Part 2 Participants : ChildPugh scale range 5 6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>